EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients

Status Completed

Clinical Trial Summary

To compare the efficacy of simultaneous EGFR-TKI and chemotherapy with that of sequential treatment after patients gradually progressed from first-line EGFR-TKI treatment.

Patients who had gradual progression and EGFR-T790M mutation-negative were randomly divided into two groups: in concurrent group, patients were treated with pemetrexed plus cisplatin along with the same EGFR-TKI; in sequential group, patients continued with EGFR-TKI until the disease progressed again according to the RECIST criteria, and then switched to chemotherapy. We evaluated progression-free survival (PFS) and overall survival (OS) time of patients. For sequential group, PFS was PFS1 (gradual progression to discontinue EGFR-TKI) plus PFS2 (chemotherapy alone).

Clinical Trial Description

According to previous reports, when non-small cell lung cancer (NSCLC) patients with EGFR mutations gradually progressed after initial EGFR tyrosine-kinase inhibitor (TKI) treatment, continuing TKI therapy may be beneficial. We aimed to compare the efficacy of simultaneous EGFR-TKI and chemotherapy with that of sequential treatment after patients gradually progressed from first-line EGFR-TKI treatment.

Patients who had gradual progression and EGFR-T790M mutation-negative were randomly divided into two groups: in concurrent group, patients were treated with pemetrexed plus cisplatin along with the same EGFR-TKI; in sequential group, patients continued with EGFR-TKI until the disease progressed again according to the RECIST criteria, and then switched to chemotherapy. We evaluated progression-free survival (PFS) and overall survival (OS) time of patients. For sequential group, PFS was PFS1 (gradual progression to discontinue EGFR-TKI) plus PFS2 (chemotherapy alone). Objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety were also evaluated. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03544814
Study type	Interventional
Source	Shanghai Chest Hospital
Contact
Status	Completed
Phase	Phase 2
Start date	January 1, 2015
Completion date	December 30, 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02898857` - Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma	N/A
Completed	`NCT02127359` - Whole-Exome Sequencing (WES) of Cancer Patients
Recruiting	`NCT01249066` - Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma	N/A
Not yet recruiting	`NCT04482829` - TCM in the Treatment of Lung Adenocarcinoma	N/A
Recruiting	`NCT04929041` - Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative	Phase 2/Phase 3
Terminated	`NCT04691375` - A Study of PY314 in Subjects With Advanced Solid Tumors	Phase 1
Terminated	`NCT02621333` - Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma	Phase 2
Active, not recruiting	`NCT02282267` - Blood Detection of EGFR Mutation For Iressa Treatment	N/A
Not yet recruiting	`NCT01942629` - Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas	N/A
Recruiting	`NCT01482585` - Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy	N/A
Recruiting	`NCT03376737` - Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma	Phase 2
Recruiting	`NCT05537922` - I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Recruiting	`NCT04937283` - Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm	N/A
Recruiting	`NCT06255197` - Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
Completed	`NCT02093000` - A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma	N/A
Recruiting	`NCT04119024` - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors	Phase 1
Terminated	`NCT04682431` - A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05736991` - Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
Enrolling by invitation	`NCT05136014` - Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model
Terminated	`NCT05012397` - Milademetan in Advanced/Metastatic Solid Tumors	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms